RESEARCH · RETATRUTIDE · GLUCAGON RECEPTOR
Retatrutide and the Glucagon Receptor: What the Mechanistic Literature Says About Energy Expenditure and the Liver
Retatrutide is described as a triple agonist at the GIP, GLP-1 and glucagon receptors. Our earlier article, Retatrutide: the phase 1–3 trial series, follows the clinical record. This article looks at the component that separates it from dual agonists such as tirzepatide, the glucagon receptor (GCGR), and at what the mechanistic literature does and does not show. PurixLab’s Retatrutide 10mg is supplied as a research material for laboratory research use only.
Why add glucagon to an incretin?
The discovery paper for the molecule describes a peptide that is a triple agonist at GCGR, GIPR and GLP-1R, with balanced GCGR and GLP-1R activity in vitro but more GIPR activity. In obese mice, weight loss was augmented by GCGR-mediated increases in energy expenditure on top of the calorie-intake reduction driven by GIPR and GLP-1R [1]. A separate mouse study of other optimised peptide triagonists reported that they normalised body weight and enhanced energy expenditure more than GLP-1R mono-agonists or GLP-1R/GIPR co-agonists, and the authors implicated GCGR activation as the differentiating factor [2]. The central idea is therefore: incretin signalling reduces intake, and glucagon is added for an energy-expenditure effect.
Does glucagon raise energy expenditure in people? Mixed evidence
A 2019 review notes that glucagon’s ability to increase energy expenditure has been known for more than 60 years, yet the mechanisms behind its thermogenic effect remain largely elusive [3]. The human studies are not uniform:
- In 11 healthy male volunteers, energy expenditure rose by 14% after cold exposure and by 15% after glucagon was infused, but no rise in brown adipose tissue activity or in noradrenaline was detected after glucagon, so the authors concluded the effect was independent of brown fat [4].
- In 31 people with overweight or obesity given intravenous glucagon for 72 hours and assessed by whole-room calorimetry, sleeping, basal and 24-hour energy expenditure did not differ from placebo. Basal fat oxidation was higher in the higher-exposure group on days 2 and 3, but 24-hour fat oxidation was unchanged [5].
- Oxyntomodulin, a natural gut hormone that acts at both receptors, was given for four days to 15 overweight or obese volunteers. Energy intake at a study meal fell by 17.3%; resting energy expenditure did not change but total energy expenditure rose by 9.4%, alongside higher activity-related energy expenditure [6].
A 2023 review states that the precise contribution and mechanism of GCGR activity to increased energy expenditure and weight loss in rodents and humans is not fully understood, and proposes an amino-acid-centred explanation involving glucagon-stimulated hypoaminoacidemia [7]. A 2026 IUPHAR review likewise relies largely on preclinical evidence, because clinical data on GCGR agonism are extremely limited, and says the mechanistic data have so far been evaluated only in rodent models [8].
The liver: lipid, ketone and amino-acid metabolism
Glucagon is best known for raising glucose, but a 2024 Physiological Reviews article describes broader hepatic actions: increased fatty-acid oxidation with attenuated lipid synthesis, plus roles in amino-acid and ketone-body metabolism and mitochondrial turnover [9]. In humans, a physiological rise in plasma glucagon increased in vivo hepatic mitochondrial oxidation by 50% to 75% in people with and without fatty liver, and raised glucose production by about 50% in the fatty-liver group, partly through about 30% higher pyruvate carboxylase flux [10]. In mice, rat livers and primary human hepatocytes, glucagon acutely increased urea formation, and steatosis may impair this glucagon-dependent amino-acid catabolism [11].
Clinically, a phase 2a liver substudy of 98 participants reported relative changes in liver fat at 24 weeks of 42.9% to 82.4% reductions across four retatrutide groups, against a 0.3% rise on placebo, with normal liver fat (below 5%) reached by 27% to 86% of participants on retatrutide versus none on placebo [12]. Because those reductions were significantly related to body weight, abdominal fat and metabolic measures [12], the study by itself does not isolate a direct glucagon-receptor effect. The parent phase 2 obesity trial reported a mean weight change of 24.2% at 48 weeks in the highest group, mostly mild-to-moderate gastrointestinal events, and heart-rate increases that peaked at 24 weeks and declined afterwards [13].
What remains unknown
- Human energy expenditure. Acute glucagon studies show an effect; a 72-hour study did not [4,5]. How much of a triple agonist’s weight loss comes from the GCGR arm in people is not established [7,8].
- Amino-acid effects. Whether glucagon-driven hypoaminoacidemia matters during weight loss remains a hypothesis [7], and steatosis may alter glucagon’s hepatic actions [11].
- Separating receptors. Preclinical comparisons use different molecules and models, and no human study cited here isolates GCGR activity within a triple agonist [1,2].
- Long-term outcomes. The liver-fat data are short-term imaging results in a substudy [12].
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. PubMed 35809773 · PMC9305623 · doi:10.1016/j.molmet.2022.101533
- Kleinert M, Sachs S, Habegger KM, et al. Glucagon Regulation of Energy Expenditure. Int J Mol Sci. 2019;20(21):5407. PubMed 31671603 · PMC6862306 · doi:10.3390/ijms20215407
- Salem V, Izzi-Engbeaya C, Coello C, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016;18(1):72-81. PubMed 26434748 · PMC4710848 · doi:10.1111/dom.12585
- Whytock KL, Carnero EA, Vega RB, et al. Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial. Obesity (Silver Spring). 2021;29(6):1003-1013. PubMed 34029448 · doi:10.1002/oby.23141
- Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12):1729-36. PubMed 16619056 · doi:10.1038/sj.ijo.0803344
- Hope DCD, Tan TM. Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy. Peptides. 2023;162:170962. PubMed 36736539 · doi:10.1016/j.peptides.2023.170962
- Elmendorf AJ, Yousefian M, Kim IM, et al. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacol Res. 2026;223:108077. PubMed 41478576 · PMC12910462 · doi:10.1016/j.phrs.2025.108077
- Kajani S, Laker RC, Ratkova E, et al. Hepatic glucagon action: beyond glucose mobilization. Physiol Rev. 2024;104(3):1021-1060. PubMed 38300523 · doi:10.1152/physrev.00028.2023
- Petersen KF, Dufour S, Mehal WZ, et al. Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease. Cell Metab. 2024;36(11):2359-2366.e3. PubMed 39197461 · PMC11612994 · doi:10.1016/j.cmet.2024.07.023
- Winther-Sørensen M, Galsgaard KD, Santos A, et al. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Mol Metab. 2020;42:101080. PubMed 32937194 · PMC7560169 · doi:10.1016/j.molmet.2020.101080
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PubMed 38858523 · PMC11271400 · doi:10.1038/s41591-024-03018-2
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972